Literature DB >> 22772468

Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Juan Guinea-Viniegra1, Rainer Zenz, Harald Scheuch, María Jiménez, Latifa Bakiri, Peter Petzelbauer, Erwin F Wagner.   

Abstract

Squamous cell carcinomas (SCCs) are heterogeneous and aggressive skin tumors for which innovative, targeted therapies are needed. Here, we identify a p53/TACE pathway that is negatively regulated by FOS and show that the FOS/p53/TACE axis suppresses SCC by inducing differentiation. We found that epidermal Fos deletion in mouse tumor models or pharmacological FOS/AP-1 inhibition in human SCC cell lines induced p53 expression. Epidermal cell differentiation and skin tumor suppression were caused by a p53-dependent transcriptional activation of the metalloprotease TACE/ADAM17 (TNF-α-converting enzyme), a previously unknown p53 target gene that was required for NOTCH1 activation. Although half of cutaneous human SCCs display p53-inactivating mutations, restoring p53/TACE activity in mouse and human skin SCCs induced tumor cell differentiation independently of the p53 status. We propose FOS/AP-1 inhibition or p53/TACE reactivating strategies as differentiation-inducing therapies for SCCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772468      PMCID: PMC3408745          DOI: 10.1172/JCI63103

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  69 in total

1.  Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses.

Authors:  Giulia Fontemaggi; Itai Kela; Ninette Amariglio; Gideon Rechavi; Janakiraman Krishnamurthy; Sabrina Strano; Ada Sacchi; David Givol; Giovanni Blandino
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

2.  Non-melanoma skin cancer.

Authors:  Vishal Madan; John T Lear; Rolf-Markus Szeimies
Journal:  Lancet       Date:  2010-02-20       Impact factor: 79.321

3.  Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.

Authors:  A W Lin; S W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

4.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

5.  Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation.

Authors:  Pinglong Xu; Rik Derynck
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

6.  ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site.

Authors:  Sylvain M Le Gall; Thorsten Maretzky; Priya D A Issuree; Xiao-Da Niu; Karina Reiss; Paul Saftig; Rama Khokha; Daniel Lundell; Carl P Blobel
Journal:  J Cell Sci       Date:  2010-10-27       Impact factor: 5.285

7.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE.

Authors:  C Brou; F Logeat; N Gupta; C Bessia; O LeBail; J R Doedens; A Cumano; P Roux; R A Black; A Israël
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

8.  The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development.

Authors:  M Sibilia; A Fleischmann; A Behrens; L Stingl; J Carroll; F M Watt; J Schlessinger; E F Wagner
Journal:  Cell       Date:  2000-07-21       Impact factor: 41.582

9.  Opposing roles for calcineurin and ATF3 in squamous skin cancer.

Authors:  Xunwei Wu; Bach-Cuc Nguyen; Piotr Dziunycz; Sungeun Chang; Yang Brooks; Karine Lefort; Günther F L Hofbauer; G Paolo Dotto
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

10.  Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice.

Authors:  Athena Chalaris; Nina Adam; Christian Sina; Philip Rosenstiel; Judith Lehmann-Koch; Peter Schirmacher; Dieter Hartmann; Joanna Cichy; Olga Gavrilova; Stefan Schreiber; Thomas Jostock; Vance Matthews; Robert Häsler; Christoph Becker; Markus F Neurath; Karina Reiss; Paul Saftig; Jürgen Scheller; Stefan Rose-John
Journal:  J Exp Med       Date:  2010-07-05       Impact factor: 14.307

View more
  30 in total

Review 1.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 2.  Cutaneous Notch signaling in health and disease.

Authors:  Craig Nowell; Freddy Radtke
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 3.  Notch as a tumour suppressor.

Authors:  Craig S Nowell; Freddy Radtke
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

Review 4.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  A miR-34a-SIRT6 axis in the squamous cell differentiation network.

Authors:  Karine Lefort; Yang Brooks; Paola Ostano; Muriel Cario-André; Valérie Calpini; Juan Guinea-Viniegra; Andrea Albinger-Hegyi; Wolfram Hoetzenecker; Ingrid Kolfschoten; Erwin F Wagner; Sabine Werner; Gian Paolo Dotto
Journal:  EMBO J       Date:  2013-07-16       Impact factor: 11.598

6.  Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer.

Authors:  Yang Sui Brooks; Paola Ostano; Seung-Hee Jo; Jun Dai; Spiro Getsios; Piotr Dziunycz; Günther F L Hofbauer; Kara Cerveny; Giovanna Chiorino; Karine Lefort; G Paolo Dotto
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

7.  The roles of NANOG in tumorigenesis.

Authors:  Jinchul Kim; Stefan Yu; Yang Xu
Journal:  Mol Cell Oncol       Date:  2015-07-29

8.  Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction.

Authors:  Craig S Nowell; Pascal D Odermatt; Luca Azzolin; Sylke Hohnel; Erwin F Wagner; Georg E Fantner; Matthias P Lutolf; Yann Barrandon; Stefano Piccolo; Freddy Radtke
Journal:  Nat Cell Biol       Date:  2015-12-21       Impact factor: 28.824

9.  Understanding allergy and cancer risk: what are the barriers?

Authors:  Esther Hoste; Sara Cipolat; Fiona M Watt
Journal:  Nat Rev Cancer       Date:  2015-02-05       Impact factor: 60.716

10.  Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.

Authors:  Alberto Martin; Fernando Salvador; Gema Moreno-Bueno; Alfredo Floristán; Cristina Ruiz-Herguido; Eva P Cuevas; Saleta Morales; Vanesa Santos; Katalin Csiszar; Pierre Dubus; Jody J Haigh; Anna Bigas; Francisco Portillo; Amparo Cano
Journal:  EMBO J       Date:  2015-03-10       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.